Data protection Impressum

Biotech

Swiss start-ups raised CHF 2.9 billion in 2025, marking a strong recovery in venture capital investment led by ICT and biotech.

Business environment

Swiss start-ups attract CHF 2.9 billion in 2025 as venture capital rebounds

3 February 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (January 2026)

30 January 2026

The Fonds pour l’Innovation et le Futur de Genève (FIF) has awarded CHF 50,000 grants to three academic spin-off projects from Geneva, supporting innovation in medical technology, scientific instrumentation, and gene therapy.

FIF awards grants to three Geneva-based academic spin-offs

29 January 2026

Geneva-based biotech start-up FluoSphera has raised CHF 1.15 million to expand its human-relevant preclinical testing platform, supporting the shift toward more predictive and non-animal drug development models.

FluoSphera raises CHF 1.15 million to scale human-based preclinical drug testing

19 January 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (December 2025)

24 December 2025

The FIT has awarded three Tech Seed loans of CHF 100,000 each to early-stage start-ups CCRAFT, Databaum and Lemna Bio.

FIT backs three start-ups to advance photonics, agritech and AI-driven drug discovery

23 December 2025

The canton of Fribourg is building a distinctive growth model at the crossroads of industry, luxury and innovation, combining precision manufacturing, advanced technologies and long-term value creation.

Fribourg: where discreet excellence powers high-value industries

17 December 2025

DigeHealth has raised CHF 1.25 million to accelerate the development of a wearable device that continuously monitors gastrointestinal activity using acoustics and artificial intelligence.

DigeHealth raises CHF 1.25 million to advance continuous gastrointestinal monitoring

15 December 2025

Researchers at CHUV have validated a new stem-cell–based method to study autoimmune diseases in organs such as the brain, offering new insights into conditions like autoimmune encephalitis and multiple sclerosis.

CHUV researchers develop new method to study autoimmune diseases

2 December 2025

Takeda has opened a new CHF 200 million biotechnology facility in Neuchâtel to expand aseptic filling capacity for rare disease therapies.

Takeda inaugurates CHF 200 million biotechnology facility in Neuchâtel

1 December 2025

1 2 3 4 5 6 7 … 19